$PBYI
PUMA BIOTECHNOLOGY, INC.

2017 Q3 Form 10-Q Financial Statement

#000156459017023226 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q4 2016 Q3
Revenue $6.077M $0.00 $0.00
YoY Change
Cost Of Revenue $1.526M
YoY Change
Gross Profit $4.551M
YoY Change
Gross Profit Margin 74.89%
Selling, General & Admin $32.49M $16.47M $14.02M
YoY Change 131.7% 71.56% 59.16%
% of Gross Profit 713.89%
Research & Development $49.50M $56.40M $51.98M
YoY Change -4.77% 7.55% 0.12%
% of Gross Profit 1087.72%
Depreciation & Amortization $900.0K $580.0K $110.0K
YoY Change 718.18% 176.19% -45.0%
% of Gross Profit 19.78%
Operating Expenses $83.52M $72.87M $14.02M
YoY Change 495.61% 17.46% -76.91%
Operating Profit -$77.44M
YoY Change
Interest Expense $310.0K $200.0K $210.0K
YoY Change 47.62% -37.5% -34.38%
% of Operating Profit
Other Income/Expense, Net $260.0K $10.00K $0.00
YoY Change -100.0%
Pretax Income -$77.18M -$72.66M -$65.78M
YoY Change 17.33% 17.73% 8.87%
Income Tax
% Of Pretax Income
Net Earnings -$77.18M -$72.66M -$65.78M
YoY Change 17.33% 17.73% 8.88%
Net Earnings / Revenue -1270.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.074M -$2.035M -$2.024M
COMMON SHARES
Basic Shares Outstanding 36.82M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.3M $229.5M $108.9M
YoY Change -2.39% 6.3% -56.05%
Cash & Equivalents $84.03M $198.8M $52.54M
Short-Term Investments $26.60M $35.00M $56.40M
Other Short-Term Assets $9.300M $7.000M $7.300M
YoY Change 27.4% -9.09% 5.8%
Inventory $100.0K
Prepaid Expenses
Receivables $3.900M $1.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $119.6M $236.5M $117.4M
YoY Change 1.87% 5.79% -53.91%
LONG-TERM ASSETS
Property, Plant & Equipment $4.700M $5.200M $5.200M
YoY Change -9.62% 118.21% 108.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.200M $11.20M $11.50M
YoY Change -28.7% -19.42% -20.14%
Total Long-Term Assets $62.30M $16.30M $16.60M
YoY Change 275.3% 0.04% -1.78%
TOTAL ASSETS
Total Short-Term Assets $119.6M $236.5M $117.4M
Total Long-Term Assets $62.30M $16.30M $16.60M
Total Assets $181.9M $252.8M $134.0M
YoY Change 35.75% 5.4% -50.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.60M $20.00M $20.90M
YoY Change -15.79% 12.34% 113.27%
Accrued Expenses $79.60M $17.40M $16.70M
YoY Change 376.65% 18.86% 7.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $97.30M $37.50M $37.60M
YoY Change 158.78% 15.59% 48.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.400M $5.500M $5.300M
YoY Change 1.89% 292.86% 253.33%
Total Long-Term Liabilities $5.400M $5.500M $5.300M
YoY Change 1.89% 292.86% 253.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $97.30M $37.50M $37.60M
Total Long-Term Liabilities $5.400M $5.500M $5.300M
Total Liabilities $102.7M $42.97M $42.90M
YoY Change 139.39% 26.99% 60.07%
SHAREHOLDERS EQUITY
Retained Earnings -$1.024B -$796.5M
YoY Change 53.03%
Common Stock $1.006B
YoY Change 38.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.17M $209.8M $91.10M
YoY Change
Total Liabilities & Shareholders Equity $181.9M $252.8M $134.0M
YoY Change 35.71% 5.4% -50.66%

Cashflow Statement

Concept 2017 Q3 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$77.18M -$72.66M -$65.78M
YoY Change 17.33% 17.73% 8.88%
Depreciation, Depletion And Amortization $900.0K $580.0K $110.0K
YoY Change 718.18% 176.19% -45.0%
Cash From Operating Activities -$54.91M -$40.96M -$34.89M
YoY Change 57.38% 24.01% -5.37%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$550.0K -$70.00K
YoY Change 128.57% 816.67% -53.33%
Acquisitions
YoY Change
Other Investing Activities $44.23M $21.39M $29.53M
YoY Change 49.78% -46.18% -743.36%
Cash From Investing Activities $44.07M $20.84M $29.47M
YoY Change 49.54% -47.49% -720.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.730M 162.1M 130.0K
YoY Change 7384.62% 12178.79% -97.58%
NET CHANGE
Cash From Operating Activities -54.91M -40.96M -34.89M
Cash From Investing Activities 44.07M 20.84M 29.47M
Cash From Financing Activities 9.730M 162.1M 130.0K
Net Change In Cash -1.110M 142.0M -5.290M
YoY Change -79.02% 1678.95% -85.41%
FREE CASH FLOW
Cash From Operating Activities -$54.91M -$40.96M -$34.89M
Capital Expenditures -$160.0K -$550.0K -$70.00K
Free Cash Flow -$54.75M -$40.41M -$34.82M
YoY Change 57.24% 22.57% -5.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Liabilities
Liabilities
42966000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1006344000
CY2017Q3 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
5653000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1024388000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
79168000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181858000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37384975
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37384975
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6077000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6077000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1526000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1526000
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32489000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14022000
us-gaap Operating Income Loss
OperatingIncomeLoss
-203726000
us-gaap Investment Income Interest
InvestmentIncomeInterest
756000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37214002
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
18000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77162000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65809000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
83213000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14002000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
565000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.07
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
2997000
us-gaap Share Based Compensation
ShareBasedCompensation
87990000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-368000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3890000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
89000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1179000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-712000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2832000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2496000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3075000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12182000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2082000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
67000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-3891000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-136861000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-100729000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
286000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3730000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
3000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
2997000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
79728000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
81794000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
88096000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
209874000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8082000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
121350000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14002000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
351000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14002000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
351000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-114777000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20972000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31569000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52541000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
105000
pbyi Licensor Fee Due In Accrued Expenses
LicensorFeeDueInAccruedExpenses
50000000
pbyi Receivables Related To Stock Option Exercises
ReceivablesRelatedToStockOptionExercises
5653000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include accrued expenses for the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events, which are difficult to predict. It is at least reasonably possible that a change in the estimates used to record accrued expenses and to value the stock-based compensation will occur in the near term. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September 30, 2017, were approximately $85.4 million. The Company does not believe it is exposed to any significant credit risk due to the quality of the financial instruments in which the money is held. Pursuant to the Company&#8217;s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor&#8217;s Corporation and Moody&#8217;s Investors Service at the time of purchase. </p></div>
CY2017Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
106300000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1000000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3900000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3900000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3900000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Seven
FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Eight
FiniteLivedIntangibleAssetsAmortizationExpenseYearEight
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Nine
FiniteLivedIntangibleAssetsAmortizationExpenseYearNine
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Ten
FiniteLivedIntangibleAssetsAmortizationExpenseYearTen
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Eleven
FiniteLivedIntangibleAssetsAmortizationExpenseYearEleven
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Twelve
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwelve
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Thirteen
FiniteLivedIntangibleAssetsAmortizationExpenseYearThirteen
3900000
CY2017Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Fourteen
FiniteLivedIntangibleAssetsAmortizationExpenseYearFourteen
1000000
CY2017Q3 pbyi Incremental Costs Expenses
IncrementalCostsExpenses
0
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
95531000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
223525000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
95524000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
223512000
CY2016Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
13844000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8102000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2949000
CY2017Q3 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
50000000
CY2017Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
621000
CY2017Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
8323000
CY2016Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
6609000
CY2017Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
7243000
CY2016Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
7015000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2806000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
706000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8486000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3058000
CY2017Q3 pbyi Accrued In Licensed Rights
AccruedInLicensedRights
50000000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2750000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38000
CY2017Q3 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
26488000
CY2016Q3 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
29751000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
83213000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
87990000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6578522
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
519791
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
272399
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
419504
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
111218
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6295192
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2333232
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
87.52
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
38.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
50.26
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
46.85
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
117.89
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
87.29
CY2017Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
58.97
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P8Y9M18D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18442000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18366000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
318349000
CY2017Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
151369000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.79
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3106083
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1020243
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
272399
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
47.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
61.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
30.28
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
35.31
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2016Q2 pbyi Number Of Shareholders Derivative Lawsuits
NumberOfShareholdersDerivativeLawsuits
2

Files In Submission

Name View Source Status
0001564590-17-023226-index-headers.html Edgar Link pending
0001564590-17-023226-index.html Edgar Link pending
0001564590-17-023226.txt Edgar Link pending
0001564590-17-023226-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pbyi-10q_20170930.htm Edgar Link pending
pbyi-20170930.xml Edgar Link completed
pbyi-20170930.xsd Edgar Link pending
pbyi-20170930_cal.xml Edgar Link unprocessable
pbyi-20170930_def.xml Edgar Link unprocessable
pbyi-20170930_lab.xml Edgar Link unprocessable
pbyi-20170930_pre.xml Edgar Link unprocessable
pbyi-ex311_10.htm Edgar Link pending
pbyi-ex312_6.htm Edgar Link pending
pbyi-ex321_8.htm Edgar Link pending
pbyi-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending